Sector Gamma AS Has $4.33 Million Stock Position in Solventum Corporation $SOLV

Sector Gamma AS grew its holdings in Solventum Corporation (NYSE:SOLV) by 55.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 59,259 shares of the company’s stock after acquiring an additional 21,259 shares during the quarter. Sector Gamma AS’s holdings in Solventum were worth $4,326,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Deseret Mutual Benefit Administrators grew its position in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares in the last quarter. UniSuper Management Pty Ltd increased its holdings in Solventum by 25.0% in the 3rd quarter. UniSuper Management Pty Ltd now owns 32,723 shares of the company’s stock valued at $2,389,000 after buying an additional 6,545 shares during the period. QV Investors Inc. increased its holdings in Solventum by 15.0% in the 3rd quarter. QV Investors Inc. now owns 235,082 shares of the company’s stock valued at $17,161,000 after buying an additional 30,690 shares during the period. Rakuten Investment Management Inc. acquired a new position in shares of Solventum in the 3rd quarter valued at approximately $1,066,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Solventum by 10.6% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 56,069 shares of the company’s stock worth $4,093,000 after acquiring an additional 5,363 shares during the period.

Analyst Ratings Changes

A number of brokerages recently issued reports on SOLV. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a research note on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Stifel Nicolaus boosted their price target on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Finally, UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $90.27.

Solventum Price Performance

Solventum stock opened at $78.91 on Friday. The stock’s 50 day moving average is $81.65 and its 200 day moving average is $75.71. Solventum Corporation has a one year low of $60.70 and a one year high of $88.20. The firm has a market cap of $13.69 billion, a P/E ratio of 9.09, a P/E/G ratio of 7.22 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter last year, the business earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has authorized a stock buyback program on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.